Numerous reports have described a role of CCR10 and its ligands in cancer although the benefits of CCR10 antagonism may be cancer-dependent: the receptor can have protumoral effects when expressed on regulatory T cells or tumor cells or antitumoral effects when expressed on CD4+ and CD8+ T cells (76, 77, 78, 79). Here, CD8A is linked to neoplasm.